Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FOLD logo FOLD
Upturn stock ratingUpturn stock rating
FOLD logo

Amicus Therapeutics Inc (FOLD)

Upturn stock ratingUpturn stock rating
$7.65
Last Close (24-hour delay)
Profit since last BUY9.44%
upturn advisory
Consider higher Upturn Star rating
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: FOLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $16.09

1 Year Target Price $16.09

Analysts Price Target For last 52 week
$16.09 Target price
52w Low $5.51
Current$7.65
52w High $12.65

Analysis of Past Performance

Type Stock
Historic Profit -22.21%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.35B USD
Price to earnings Ratio -
1Y Target Price 16.09
Price to earnings Ratio -
1Y Target Price 16.09
Volume (30-day avg) 12
Beta 0.53
52 Weeks Range 5.51 - 12.65
Updated Date 08/24/2025
52 Weeks Range 5.51 - 12.65
Updated Date 08/24/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.12

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.11
Actual 0.01

Profitability

Profit Margin -6.67%
Operating Margin (TTM) -5.02%

Management Effectiveness

Return on Assets (TTM) 2%
Return on Equity (TTM) -22.62%

Valuation

Trailing PE -
Forward PE 285.71
Enterprise Value 2558018636
Price to Sales(TTM) 4.11
Enterprise Value 2558018636
Price to Sales(TTM) 4.11
Enterprise Value to Revenue 4.48
Enterprise Value to EBITDA 77.37
Shares Outstanding 308239008
Shares Floating 288206897
Shares Outstanding 308239008
Shares Floating 288206897
Percent Insiders 0.72
Percent Institutions 104.75

ai summary icon Upturn AI SWOT

Amicus Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Amicus Therapeutics Inc. was founded in 2002. It is a global biotechnology company focused on discovering, developing, and delivering medicines for rare diseases.

business area logo Core Business Areas

  • Global Pompe: Development and commercialization of therapies for Pompe disease, including AT-GAA (cipaglucosidase alfa and miglustat) now known as Pombiliti + Opfolda. These therapies are the primary revenue drivers of the company.
  • Chaperone Technology: Developing pharmacological chaperones to treat a variety of genetic diseases by stabilizing misfolded proteins.
  • Gene Therapy: Researching and developing gene therapies for other rare diseases including CLN6 Batten disease.

leadership logo Leadership and Structure

John F. Crowley is the Chairman and Chief Executive Officer. The company has a typical biotechnology organizational structure with research, development, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Pombiliti + Opfolda: A two-component therapy (cipaglucosidase alfa and miglustat) for late-onset Pompe disease (LOPD). Launched in the US in May 2024, and previously launched in the UK and EU. The primary competitor is Nexviazyme (avalglucosidase alfa) from Sanofi. Market share data is still evolving with initial launch. This is the primary revenue driver for Amicus and expected to drive growth for the next 10 years.
  • Galafold (migalastat): An oral pharmacological chaperone approved for Fabry disease in patients with amenable mutations. Competitors include enzyme replacement therapies (ERTs) like Fabrazyme (Sanofi) and Replagal (Takeda). Galafold has a significant share of the Fabry market within the amenable mutation subset, however this is slowly being eroded by ERTs due to their wider patient label.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high research and development costs, long regulatory pathways, and significant competition. The rare disease market is a growing segment due to unmet medical needs and regulatory incentives.

Positioning

Amicus Therapeutics Inc. focuses on rare diseases, giving it a niche position. The company's strength lies in its expertise in protein folding and chaperone technology. However, its dependence on a few key products makes it vulnerable to competition.

Total Addressable Market (TAM)

The total addressable market for Pompe disease and Fabry disease combined is estimated to be several billion dollars annually. Amicus is positioned to capture a significant portion of this TAM with its approved therapies.

Upturn SWOT Analysis

Strengths

  • Approved therapies for Pompe and Fabry diseases
  • Strong expertise in protein folding and chaperone technology
  • Established commercial infrastructure in key markets
  • Deep pipeline of potential therapies

Weaknesses

  • High dependence on a limited number of products
  • Intense competition in the rare disease market
  • Significant debt burden
  • Regulatory and reimbursement risks

Opportunities

  • Expansion into new markets and indications
  • Advancement of pipeline programs
  • Strategic partnerships and acquisitions
  • Increased awareness and diagnosis of rare diseases

Threats

  • Competition from established pharmaceutical companies
  • Patent expirations
  • Adverse regulatory decisions
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • TAK

Competitive Landscape

Amicus has a competitive advantage in certain rare disease markets due to its focus on pharmacological chaperones and gene therapies. However, larger pharmaceutical companies with greater resources pose a significant threat. Sanofi (SNY) and Takeda (TAK) are significant competitors with established products and infrastructure.

Major Acquisitions

Callidus Biopharma

  • Year: 2017
  • Acquisition Price (USD millions): 130
  • Strategic Rationale: Expanded Amicus' pipeline into gene therapy for rare diseases.

Growth Trajectory and Initiatives

Historical Growth: Revenue growth has been driven by sales of Galafold and more recently, Pombiliti + Opfolda. The company has invested heavily in research and development to expand its pipeline.

Future Projections: Analysts predict continued revenue growth driven by Pombiliti + Opfolda and potential new product launches. Profitability is expected to improve as the company scales its operations.

Recent Initiatives: The launch of Pombiliti + Opfolda for Pompe disease, advancement of gene therapy programs, and expansion into new markets.

Summary

Amicus Therapeutics is a biotechnology company specializing in rare diseases, demonstrating promise with therapies like Pombiliti + Opfolda. High R&D costs contribute to net losses, while revenue growth depends on successful product launches. Competition from larger companies and regulatory risks remain threats. Focusing on pipeline development and strategic partnerships is crucial for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Amicus Therapeutics Inc

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2007-05-31
CEO, President & Director Mr. Bradley L. Campbell M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 499
Full time employees 499

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.